Strategies for iron supplementation: Oral versus intravenous

Kidney International, Supplement

Volumn 55, Issue 69, 1999, Pages

  Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anaphylaxis; Bone marrow; Epoetin therapy; Hypochromic red cells; Renal anemia; Transferrin

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS FUMARATE; FERROUS SUCCINATE; FERROUS SULFATE; IRON; IRON COMPLEX; IRON DEXTRAN; IRON POLYMALTOSE; IRON SACCHARATE; IRON SORBITEX; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG FORMULATION; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON INTAKE; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; METABOLISM;

ADMINISTRATION, ORAL; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FERRITINS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; IRON; IRON, DIETARY; KIDNEY FAILURE, CHRONIC;

EID: 0032949266     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.055suppl.69061.x     Document Type: Review

References (33)

1. MACDOUGALL IC: Poor response to erythropoietin: practical guidelines on investigation and management Nephrol Dial Transplant 10:607-614, 1995
2. MACDOUGALL IC: Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens 3:620-625, 1994
3. BONNAR J, GOLDBERG A, SMITH JA: Do pregnant women take their iron? Lancet 1:457-458, 1969
4. KOOISTRA MP, VAN ES A, STRUYVENBERG A, MARX JJM: Low iron absorption in erythropoietin-treated hemodialysis patients. (abstract) J Am Soc Nephrol 6:543, 1995
5. MACDOUGALL IC, HUTION RD, CAVILL I, COLES GA, WILLIAMS JD: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ 299:157-158, 1989
6. ALLEGRA V, MENGOZZI G, VASILE A: Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and three different iron treatments. Nephron 57:175-182, 1991
7. WINGARD RL, PARKER RA, ISMAIL N, HAKIM RA: Efficacy of oral iron therapy in patients receiving rhEPO. Am J Kidney Dis 25:433-439, 1995
8. MARKOWITZ GS, KAHN GA, FEINGOLD RE, COCO M, LYNN RI: An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 48:34-40, 1997
9. MACDOUGALL IC, CHANDLER G, ARMSTRONG A, BREEN C, HARCHOWAL J, CAVILL I: Characterisation of iron availability from 3 different IV iron preparations in dialysis patients. (abstract) J Am Soc Nephrol 8:221, 1997
10. ZANEN AL, ADRIAANSEN HJ, VAN BOMMEL EFH, POSTHUMA R, DE JONG GMT: "Oversaturation" of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 11:820-824, 1996
11. CHANDLER G, HARCHOWAL J, MACDOUGALL IC: Intravenous iron hydroxysaccharate: establishing the optimum dose. (abstract) J Am Soc Nephrol 8:217, 1997
12. CARTER RA, HAWKINS JB, ROBINSON BHB: Iron metabolism in the anaemia of chronic renal failure: Effects of dialysis and of parenteral iron. BMJ 3:206, 1969
13. STRICKLAND ID, CHAPUT DE SAINTONGE DM, BOULTON FE, FRANCIS B, ROUBIKOVA J, WATERS JI: The therapeutic equivalence of oral and intravenous iron in renal dialysis patients. Clin Nephrol 7:55-57, 1977
14. SILVERBERG DS, IAINA A, PEER G, KAPLAN E, LEVI BA, FRANK N, STEINBRUCH S, BLUM M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996
15. CAVILL I: Disorders of iron metabolism. Diagnostic methods. Clinics in Haematology 11:259-275, 1982
16. SCHAEFER RM, SCHAEFER L: Management of iron substitution durine r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 3:71-75, 1992
17. NYVAD O, DANIELSEN H, MADSEN S: Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet 344:1305-1306, 1994
18. AL-MOMEN AM, HURAIB SO, MITWALLI AH, AL-WAKEEL J, AL-YAMANI MJMS, ABU-AISHA H, SAID R: Intravenous iron saccharate in hemodialysis patients receiving r-HuEPO. Saudi J Kidney Dis Transplant 5:168-172, 1994
19. SUNDER-PLASSMANN G, HÖRL WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
20. FISHBANE S, FREI GL, MAESAKA J: Reduction in recombinant human crythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
21. ROSENLOF K, KIVIVUORI SM, GRONHAGEN-RISKA C, TEPPO AM, SLIMES MA: Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 43:249-255, 1995
22. MACDOUGALL IC, TUCKER B, THOMPSON J, TOMSON CRV, BAKER LRJ, RAINE AEG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1996
23. SILVERBERG DS, BLUM M, PEER G, KAPLAN E, IAINA A: Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72:413-417, 1996
24. SEPANDJ F, JINDAL K, WEST M, HIRSCH D: Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11:319-322, 1996
25. TAYLOR JE, PEAT N, PORTER C, MORGAN AG: Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11:1079-1083, 1996
26. AHSAN N, GROFF JA, WAYBILL MA: Efficacy of bolus intravenous iron dexiran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dial 12:161-166, 1996
27. BRAUN J, LINDNER K, SCHREIBER M, HEIDLER RA, HÖRL WH: Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 12:1173-1181, 1997
28. ST. PETER WL. LAMBRECHT LJ, MACRES M: Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 28:523-528, 1996
29. FISHBANE S, UNGUREANU VD, MAESAKA JK, KAUPKE CJ, LIM V, WISH J: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529-534, 1996
30. SULLIVAN JL: Iron and the sex difference in heart disease risk. Lancet 1:1293-1294, 1981
31. ASCHERIO A, WILLET WC: Are body iron stores related to the risk of coronary heart disease? N Engl J Med 330:1152-1153, 1994
32. SUSSMAN HH: Iron in cancer. Pathobiology 60:2-9, 1992
33. WEINBERG ED: Iron withholding: A defense against infection and neoplasia. Physiol Rev 64:65-102, 1984